GlassScriptPhysician profile
Trishul Siddharthan
NPI 1073802286
$50,765.88
in general payments reported to CMS, 2019-2025
14 companies · $45K in 2025
The $45K reported for 2025 was more than what 97% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $24.26 · 2023: $101 · 2024: $5,861 · 2025: $45K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $26K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $18K · Food and Beverage: $3,423 · Travel and Lodging: $2,991.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $26,452.90 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $17,875.00 |
| Food and Beverage | $3,422.87 |
| Travel and Lodging | $2,990.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $14,828.52 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $13,962.48 | 2022-2025 | Fasenra, Breztri, Tezspire |
| Genentech USA, INC. | $12,335.34 | 2025 | |
| Glaxosmithkline, LLC. | $6,090.40 | 2023-2025 | Nucala |
| Aero US INC | $2,971.90 | 2025 | Aerogen Solo Nebulizer System, Aerogen Usb Controller System, Aerogen Solo; Aerogen Ultra |
| Verona Pharma, INC. | $231.46 | 2025 | Ohtuvayre |
| 4dmedical USA INC | $142.05 | 2023-2024 | Xv Lvas, Ct Lvas, Ct Lvas |
| Regeneron Pharmaceuticals, INC. | $125.77 | 2025 | Dupixent |
| Abbvie INC. | $21.72 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $21.11 | 2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $19.13 | 2024 | Glassia |
| Pulmonx Corporation | $16.00 | 2025 | Zephyr Endobronchial Valve, Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Trishul Siddharthan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.